Results 161 to 170 of about 48,610 (212)

Recent progress in the treatment of cancer in children

Ca-A Cancer Journal for Clinicians, 2021
Theodore W Laetsch
exaly  

Anti-arrhythmia agents.

La Clinica terapeutica, 1977
G, Bracchi, F, Vezzoli
openaire   +1 more source

Improving the outcome for children with cancer: Development of targeted new agents

Ca-A Cancer Journal for Clinicians, 2015
Peter C Adamson
exaly  

Epithelial ovarian cancer: Evolution of management in the era of precision medicine

Ca-A Cancer Journal for Clinicians, 2019
Stephanie Lheureux, Marsela Braunstein, Amit M Oza   +2 more
exaly  

Treatment of renal cell carcinoma: Current status and future directions

Ca-A Cancer Journal for Clinicians, 2017
Pedro Coelho Barata, Brian I Rini
exaly  

An update on the immune landscape in lung and head and neck cancers

Ca-A Cancer Journal for Clinicians, 2020
Jennifer W Carlisle, Taofeek Kunle Owonikoko, Nabil F Saba   +2 more
exaly  

[Arrhythmogenic anti-arrhythmia agents].

Cardiology, 1983
H, Löllgen, M H, Hust, K, Nitsche, H, Wollschläger, T, Bonzel, H, Just   +5 more
openaire   +1 more source

[Ventricular cardiac arrhythmias. New anti-arrhythmia agents].

Zeitschrift fur Kardiologie, 1997
The CAST studies have shown that class I antiarrhythmic agents cause an increase in mortality in patients with ventricular tachyarrhythmias after myocardial infarction. This led to an increase in the use of class III agents. The most important class III antiarrhythmic substances are amiodarone and sotalol.
openaire   +1 more source

Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management

Ca-A Cancer Journal for Clinicians, 2016
Giuseppe Curigliano, Daniela Maria Cardinale, Susan Dent   +2 more
exaly  

An update on larynx cancer

Ca-A Cancer Journal for Clinicians, 2017
Kristin A Higgins, Nabil F Saba
exaly